T here are several examples of therapies that have differential effects in specific racially or ethnically distinct subgroups of the US population. For example, persons of African heritage generally have a poorer blood pressure response to angiotensin-converting enzyme inhibitors and ␤-blockers in comparison with whites, but they derive greater benefit in the prevention of heart failure from the combination of isosorbide dinitrate and hydralazine. Indeed, this latter finding led to the first drug approved to treat a disease in patients identified by race. The explanations for racial and ethnic differences in response may be related to genetic factors that determine drug exposure (ie, differences in absorption, distribution, metabolism, and elimination), intrinsic factors (eg, age, sex, weight, renal and/or hepatic function), extrinsic influences (eg, diet, concomitant medications and nontraditional therapies, environmental exposure, and cultural factors), or a combination therein.
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The US Food and Drug Administration has long recognized the importance of evaluating the safety and efficacy of new therapies in standardized racial and ethnic subgroups. 1 In 1998 they published the Demographic Rule (CFR 314.50 days(5)) and followed this in 2005 with a guidance document (http://www.fda.gov/downloads/RegulatoryInformation/ Guidances/ucm126396.pdf) that provided recommendations for the collection of race and ethnicity data in clinical trials. Specifically in patients with ST-elevation myocardial infarction, the clinical review (http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm126396.pdf) of tenecteplase by the Food and Drug Administration Medical Officer raised a concern regarding worse clinical outcomes among individuals of African descent. Because patients of African descent were underrepresented and there was no identification of Hispanic ethnicity were collected, the US Food and Drug Administration reviewer recommended that such data should be obtained in phase 4 trials.
Although no dedicated large phase 4 trials of fibrinolytic therapy in these underrepresented racial and ethnic subgroups have been performed to date, in this issue of Circulation, Because the proportion of patients in the analysis who received fibrinolysis and primary percutaneous coronary intervention (PPCI) were nearly equal, and these 2 distinct methods of reperfusion vary in the distribution of bleeding sites (ie, more intracranial bleeding with fibrinolysis, more access site bleeding with PPCI), the authors present analyses that appropriately separated the population by mode of reperfusion. The major focus was a comparison of moderate or major bleeding between African Americans and whites. Major bleeding was defined as bleeding that was intracranial, resulted in hemodynamic compromise requiring treatment, or was fatal. Moderate bleeding was defined as bleeding that required transfusion. Secondary analyses examined the association of race and bleeding (individually and together) on in-hospital mortality, Multivariate logistic regression models were constructed to adjust for differences in baseline characteristics and treatments, center-level effects, and possible interaction of race by reperfusion mode (fibrinolysis versus PPCI).
The authors report 3 primary findings. First, adjusted bleeding rates were higher in African Americans than in whites, whether treated with fibrinolysis (adjusted odds ratio 1.21) or PPCI (adjusted odds ratio 1.33). Second, adjusted in-hospital mortality was similar between African American and whites regardless of the method of reperfusion. Third, patients who had a moderate or major bleed (regardless of race or reperfusion type) were less likely to survive the index hospitalization than those who did not bleed.
Each of these observations deserves consideration. It has been known since the early days of fibrinolytic megatrials Ͼ2 decades ago that African Americans have higher rates of bleeding with fibrinolytic therapy, 3 possibly related to a more pronounced fall in fibrinogen observed after 5 hours. 4 The current analysis extends the prior, 3 and more contemporary 5 findings from clinical trials to a broader registry population that, most importantly, also includes patients treated with PPCI. It should be noted, however, that in the analysis by Mehta: (1) the vast majority of bleeding events were associated with transfusion, (2) African Americans were transfused more frequently than whites, and (3) no breakdown of major versus moderate bleeding or of each of the 3 components of major bleeding was provided. Furthermore, the authors appropriately caution that "unmeasured confounders may have accounted for some or all of the variations seen in bleeding"; this is particularly relevant because the definition of moderate bleeding depended on the use of transfusion. Nevertheless, variation in the decision to transfuse patients cannot explain
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From all of the findings, because African Americans treated with fibrinolytics experienced a Ͼ50% higher rate of intracranial hemorrhage (Pϭ0.011) in comparison with whites, despite being 6 years younger on average. Therefore, the reasons why African Americans with ST-elevation myocardial infarction treated with reperfusion therapy have higher rates of bleeding are likely complex and multifactorial. To get to the next level of understanding, more details on the types of bleeding, analysis of alternative bleeding definitions, 6 and collection of additional potential confounding factors that are known to be associated with bleeding (eg, combination antithrombotic therapy, excess dosing of antithrombotics, baseline hemoglobin, and presence of peripheral vascular disease) 7 are needed. The second major finding confirmed prior analyses from clinical trials spanning the previous 4 decades 4, 8, 9 that there is no difference in adjusted short-term mortality between African Americans and whites, once adjustment is introduced for baseline characteristics. Data are conflicting regarding the independent contribution of race to longer-term mortality. 4, 8, 10 An important contribution from the analysis by Mehta et al 2 is to extend the previous findings of similarly adjusted short-term mortality between these 2 racial groups now to registry patients treated with PPCI in the modern era.
The final set of analyses explored the relationships between bleeding and mortality, overall and stratified by race. The major risk factors for bleeding among patients receiving fibrinolytic therapy were described in the early megatrials, 11, 12 with more recent research focusing on the development of quantitative risk scores 13 and risk mitigation. 14 African Americans and whites in National Registry of Myocardial Infarction-4 and -5 who experienced a moderate or severe bleed had higher mortality than those of the same race who did not bleed, with no evidence of modification in the effect due to race. This then raises the question, why, if African Americans had more bleeding, and bleeding was associated with a significant increase in mortality, should we not expect a higher mortality in African Americans?
Determining the extent (if any) of a causal relationship between 2 postbaseline clinical events in a registry data set is fraught with confounding and bias. Then, incorporating yet another variable (race) that itself demonstrates significant variation in baseline characteristics that are associated with a potential cause (bleeding), and the measured effect (mortality), as well, makes any analysis treacherous. The nature of the relationship between bleeding and mortality is controversial, with some analyses concluding that this represents an association highly confounded by comorbidities, 15 whereas others report a strong independent relationship. 13 To further muddle matters, transfusion itself has been associated with increased mortality in patients with acute coronary syndromes 16 and specifically in patients with ST-elevation myocardial infarction undergoing PPCI, 17 with several possible mechanisms proposed. 18 The role played by transfusion is particularly relevant in the work by Mehta et al, 2 because the majority of bleeding events were managed with transfusion. The relationship between bleeding and mortality is also complicated by the marked differences in fatality rates dependent on the location of the bleed (intracranial versus nonintracranial), 19 which varied 10-fold between patients receiving fibrinolysis and those undergoing PPCI in National Registry of Myocardial Infarction-4 and -5. Additional considerations include the occurrence of other intervening medical events that themselves may lead to bleeding and death (eg, cardiogenic shock) and the biological plausibility of the relationship given the reported cause(s) of death. 19 Unfortunately, similar to Operation Market Garden, 20 in which overstretched Allied forces failed to hold positions crossing over the River Rhine, thereby coining the infamous phrase "a bridge too far," the authors have overextended their data, speculating that higher rates of bleeding in African Americans may explain higher long-term mortality observed in other data sets. In fact, temporal analyses of bleeding and mortality demonstrate a waning of the strength of the association as the time interval increases, 21 with no significant effect after 40 days. 21 In addition, a landmark analysis from the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment, Thrombolysis in Myocardial Infarction-Study 25 (ExTRACT-TIMI 25) trial showed no independent relationship between either nonintracranial TIMI major bleeding in hospital and death at 31 to 365 days, or TIMI minor bleeding in hospital and death at 31 to 365 days, once baseline characteristics were included in multivariate models. 19 Nevertheless, reducing bleeding is ipso facto desirable, and position statements 22 have endorsed attempts to reduce bleeding in patients with acute coronary syndromes. Several promising strategies, such as use of radial arterial access 23 and safer anticoagulants 24 are rapidly being implemented, contributing to a recent decline in bleeding rates. 25 In the meantime, specific focus on the cause and prevention of bleeding in high-risk groups, including African Americans, should be a priority.
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